197.28
-0.23 (-0.12%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | BeiGene, Ltd. | Bullish | Bearish |
Stockmoo Score
|
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene’s key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Growth |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Baker Bros. Advisors Lp | 30 Jun 2024 | 10,568,897 |
| Hhlr Advisors, Ltd. | 30 Jun 2024 | 5,176,906 |
| Primecap Management Co/Ca/ | 30 Jun 2024 | 4,986,289 |
| Capital International, Inc./Ca/ | 30 Jun 2024 | 855,134 |
| Boxer Capital, Llc | 30 Jun 2024 | 500,000 |
| Public Investment Fund | 30 Jun 2024 | 354,385 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 288.00 (JMP Securities, 45.99%) | Buy |
| 288.00 (Citigroup, 45.99%) | Buy | |
| Median | 244.00 (23.68%) | |
| Low | 152.50 (B of A Securities, -22.70%) | Hold |
| Average | 232.13 (17.67%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 179.76 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 18 Sep 2024 | 288.00 (45.99%) | Buy | 197.28 |
| JP Morgan | 20 Aug 2024 | 200.00 (1.38%) | Buy | 194.21 |
| Citigroup | 08 Aug 2024 | 288.00 (45.99%) | Buy | 183.03 |
| B of A Securities | 09 Jul 2024 | 152.50 (-22.70%) | Hold | 144.53 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |